Biparametric MRI-based radiomics for noninvastive discrimination of benign prostatic hyperplasia nodules (BPH) and prostate cancer nodules: a bio-centric retrospective cohort study

Le résumé fourni par la source

To investigate the potential of an MRI-based radiomic model in distinguishing malignant prostate cancer (PCa) nodules from benign prostatic hyperplasia (BPH)-, as well as determining the incremental value of radiomic features to clinical variables, such as prostate-specific antigen (PSA) level and Prostate Imaging Reporting and Data System (PI-RADS) score. A restrospective analysis was performed on a total of 251 patients (training cohort, n = 119; internal validation cohort, n = 52; and external validation cohort, n = 80) with prostatic nodules who underwent biparametric MRI at two hospitals between January 2018 and December 2020. A total of 1130 radiomic features were extracted from each MRI sequence, including shape-based features, gray-level histogram-based features, texture features, and wavelet features. The clinical model was constructed using logistic regression analysis. Radiomic models were created by comparing seven machine learning classifiers. The useful clinical variables and radiomic signature were integrated to develop the combined model. Model performance was assessed by receiver operating characteristic curve, calibration curve, decision curve, and clinical impact curve. The ratio of free PSA to total PSA, PSA density, peripheral zone volume, and PI-RADS score were independent determinants of malignancy. The clinical model based on these factors achieved an AUC of 0.814 (95% CI: 0.763-0.865) and 0.791 (95% CI: 0.742-840) in the internal and external validation cohorts, respectively. The clinical-radiomic nomogram yielded the highest accuracy, with an AUC of 0.925 (95% CI: 0.894-0.956) and 0.872 (95% CI: 0.837-0.907) in the internal and external validation cohorts, respectively. DCA and CIC further confirmed the clinical usefulness of the nomogram. Biparametric MRI-based radiomics has the potential to noninvasively discriminate between-BPH and malignant PCa nodules, which outperforms screening strategies based on PSA and PI-RADS.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.